News
News & announcements
Updates on our pipeline, our team, and the progress of our bispecific antibody programmes.
-
Bivalent Bio presents preclinical data for BVB-101 at AACR Annual Meeting
Bivalent Bio shared new preclinical data for its lead bispecific programme, BVB-101, demonstrating dose-dependent tumour regression in relevant in vivo models and a favourable selectivity profile consistent with conditional immune activation in the tumour microenvironment.
Read more → -
Bivalent Bio appoints Vice President of CMC as IND-enabling activities accelerate
The company strengthened its leadership with the appointment of a Vice President of CMC, bringing deep process development and GMP manufacturing experience as BVB-101 advances through IND-enabling studies.
Read more → -
Bivalent Bio closes seed extension to advance lead bispecific programme
Bivalent Bio announced the close of a seed extension financing. Proceeds will fund IND-enabling studies for BVB-101 and support continued discovery across the company's bispecific antibody portfolio.
Read more →
Media & partnership enquiries
For press, partnership, or investor enquiries, please get in touch.